Answers are grounded in this paper and cite their sources.
In 2025, China’s National Medical Products Administration (NMPA) approved a total of 76 novel drugs for marketing. Among these, small-molecule drugs accounted for 42 approvals (55%), remaining the main driving force of pharmaceutical innovation and representing a substantial increase compared with previous years. Notably, 38 small-molecule drugs received their first global approvals in China (81%), while 7 were first approved by other regulatory authorities and subsequently approved by the NMPA. This milestone underscores the remarkable advancement of China’s pharmaceutical innovation capacity in both quantity and quality. Emerging therapeutic modalities and more complex molecular architectures including deuterated, spirocyclic, bridged-ring and macromolecular entities, have expanded the drug landscape beyond traditional small molecules. In terms of therapeutic areas, oncologic drugs remained the dominant category, with 19 approvals. Significant progress was also achieved in the anti-infective field, including four novel influenza drugs and one oral anti-coronavirus disease 2019 (COVID-19) agent. Additionally, new drugs were approved for metabolic cardiovascular, respiratory, antiallergic, musculoskeletal, gastrointestinal, urinary, and autoimmune diseases. Notably, breakthroughs such as the first-in-class approved polymerase basic protein 2 (PB2) inhibitor onradivir, and olgotrelvir, the first dual-target inhibitor of 3CL protease and cathepsin L (CTSL), along with orphan drugs and priority medicines (PRIME), provide important solutions for addressing critical unmet medical needs. By dissecting the biological mechanisms, target interactions, clinical data, and chemical synthetic routes, this review provides a comprehensive overview of these small-molecule drugs and offers strategic insights to advance future drug research and development.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: